Lakewood-Amedex Biotherap... (LABT)
NasdaqCM: LABT
· Ціна в реальному часі · USD
2.27
-0.06 (-2.58%)
На закритті: Aug 14, 2026, 3:59 PM
2.17
-4.32%
Післяторговельна сесія: 7:59 PM
Опис компанії
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Lakewood-Amedex Biotherapeutics Inc.

| Країна | United States |
| Дата IPO | 23 квіт. 2026 р. |
| Галузь | Biotechnology |
| Сектор | Healthcare |
| Працівники | 5 |
| CEO | Dr. Kelvin Cooper Ph.D. |
Контактні дані
Адреса: 8031 Cooper Creek Blvd. University Park, FL United States | |
| Сайт | https://lakewoodamedex.com |
Дані про акцію
| Тікер | LABT |
| Біржа | NasdaqCM |
| Фінансовий рік | Jan '25 - Dec '25 |
| Валюта звітності | USD |
| Код CIK | 0002079272 |
| Номер CUSIP | n/a |
| Номер ISIN | n/a |
| Ідентифікатор роботодавця | n/a |
| Код SIC | n/a |
Ключові керівники
| Ім'я | Посада |
|---|---|
| Dr. Kelvin Cooper Ph.D. | CEO, SVP of Research & Development and Director |
| Mr. Peter F. Ceccacci | CFO & VP of Administration |
| Dr. Thomas Balzer M.D., Ph.D. | Chief Medical Officer & SVP of Clinical Development |
| Ms. Tara Endress | Project Manager & Accounting Manager |
| Daniel Kontoh-Boateng | Investor Relations |
